Eribulin treatment for patients with metastatic breast cancer: The UK Experience - A Multicenter Retrospective Study

Mariam Jafri; Hartmut Kristeleit; Vivek Misra; Mark Baxter; Samreen Ahmed; Apurna Jegannathen; Ankit Jain; David Maskell; Urmila Barthakur; Gwenllian Edwards; Harriet S. Walter; Richard Walshaw; Madeha Khan; Annabel Borley; Daniel Rea

doi:10.1159/000526140

Eribulin treatment for patients with metastatic breast cancer: The UK Experience - A Multicenter Retrospective Study

Mariam Jafri (Lead / Corresponding author), Hartmut Kristeleit, Vivek Misra, Mark Baxter, Samreen Ahmed, Apurna Jegannathen, Ankit Jain, David Maskell, Urmila Barthakur, Gwenllian Edwards, Harriet S. Walter, Richard Walshaw, Madeha Khan, Annabel Borley, Daniel Rea

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

76 Downloads (Pure)

Abstract

Introduction: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK.

Methods: Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS).

Results: Among 577 patients analyzed, the median age was 56 years, and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261-315), and the PFS was 117 days (95% CI: 105-129). The median OS was higher among older patients (≥65 vs. <65 years: 325 days [95% CI: 264-385] vs. 285 days [95% CI: 252-317]; p = 0.028). The median OS was also higher in patients who received eribulin after fewer prior lines of chemotherapy (≤2 vs. >2 prior: 328 days [95% CI: 264-385] vs. 264 days [95% CI: 229-298]; p = 0.042).

Discussion/Conclusion: These retrospective data suggest that eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings, which, while predictable, supports consideration of eribulin as a second-line treatment option.

Original language	English
Pages (from-to)	666-673
Number of pages	8
Journal	Oncology
Volume	100
Issue number	12
Early online date	31 Aug 2022
DOIs	https://doi.org/10.1159/000526140
Publication status	Published - Dec 2022

Keywords

eribulin
observation study
real-world
metastatic breast cancer
older adults
second-line
Observation study
Second-line treatment
Eribulin
Real-world data
Metastatic breast cancer
Older adults

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000526140Licence: CC BY-NC

Final published versionFinal published version, 394 KBLicence: CC BY-NC

Cite this

Jafri, M., Kristeleit, H., Misra, V., Baxter, M., Ahmed, S., Jegannathen, A., Jain, A., Maskell, D., Barthakur, U., Edwards, G., Walter, H. S., Walshaw, R., Khan, M., Borley, A., & Rea, D. (2022). Eribulin treatment for patients with metastatic breast cancer: The UK Experience - A Multicenter Retrospective Study. Oncology, 100(12), 666-673. https://doi.org/10.1159/000526140

@article{9f2051716cb84ec1ba2e27ba4cc0c8c0,

title = "Eribulin treatment for patients with metastatic breast cancer: The UK Experience - A Multicenter Retrospective Study",

abstract = "Introduction: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK.Methods: Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS).Results: Among 577 patients analyzed, the median age was 56 years, and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261-315), and the PFS was 117 days (95% CI: 105-129). The median OS was higher among older patients (≥65 vs. <65 years: 325 days [95% CI: 264-385] vs. 285 days [95% CI: 252-317]; p = 0.028). The median OS was also higher in patients who received eribulin after fewer prior lines of chemotherapy (≤2 vs. >2 prior: 328 days [95% CI: 264-385] vs. 264 days [95% CI: 229-298]; p = 0.042).Discussion/Conclusion: These retrospective data suggest that eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings, which, while predictable, supports consideration of eribulin as a second-line treatment option.",

keywords = "eribulin, observation study, real-world, metastatic breast cancer, older adults, second-line, Observation study, Second-line treatment, Eribulin, Real-world data, Metastatic breast cancer, Older adults",

author = "Mariam Jafri and Hartmut Kristeleit and Vivek Misra and Mark Baxter and Samreen Ahmed and Apurna Jegannathen and Ankit Jain and David Maskell and Urmila Barthakur and Gwenllian Edwards and Walter, {Harriet S.} and Richard Walshaw and Madeha Khan and Annabel Borley and Daniel Rea",

note = "Funding Information: Eisai Company Limited provided financial assistance for the statistical analysis of the data.",

year = "2022",

month = dec,

doi = "10.1159/000526140",

language = "English",

volume = "100",

pages = "666--673",

number = "12",

}

Jafri, M, Kristeleit, H, Misra, V, Baxter, M, Ahmed, S, Jegannathen, A, Jain, A, Maskell, D, Barthakur, U, Edwards, G, Walter, HS, Walshaw, R, Khan, M, Borley, A & Rea, D 2022, 'Eribulin treatment for patients with metastatic breast cancer: The UK Experience - A Multicenter Retrospective Study', Oncology, vol. 100, no. 12, pp. 666-673. https://doi.org/10.1159/000526140

TY - JOUR

T1 - Eribulin treatment for patients with metastatic breast cancer

T2 - The UK Experience - A Multicenter Retrospective Study

AU - Jafri, Mariam

AU - Kristeleit, Hartmut

AU - Misra, Vivek

AU - Baxter, Mark

AU - Ahmed, Samreen

AU - Jegannathen, Apurna

AU - Jain, Ankit

AU - Maskell, David

AU - Barthakur, Urmila

AU - Edwards, Gwenllian

AU - Walter, Harriet S.

AU - Walshaw, Richard

AU - Khan, Madeha

AU - Borley, Annabel

AU - Rea, Daniel

N1 - Funding Information: Eisai Company Limited provided financial assistance for the statistical analysis of the data.

PY - 2022/12

Y1 - 2022/12

N2 - Introduction: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK.Methods: Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS).Results: Among 577 patients analyzed, the median age was 56 years, and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261-315), and the PFS was 117 days (95% CI: 105-129). The median OS was higher among older patients (≥65 vs. <65 years: 325 days [95% CI: 264-385] vs. 285 days [95% CI: 252-317]; p = 0.028). The median OS was also higher in patients who received eribulin after fewer prior lines of chemotherapy (≤2 vs. >2 prior: 328 days [95% CI: 264-385] vs. 264 days [95% CI: 229-298]; p = 0.042).Discussion/Conclusion: These retrospective data suggest that eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings, which, while predictable, supports consideration of eribulin as a second-line treatment option.

AB - Introduction: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK.Methods: Anonymized data were collected retrospectively from patients with MBC who had received eribulin. The data included the hormone-receptor status, histological diagnosis, age, prior chemotherapy, response to eribulin, progression-free survival (PFS), and overall survival (OS).Results: Among 577 patients analyzed, the median age was 56 years, and most patients (73%) were estrogen-receptor positive. The median OS was 288 days (95% confidence interval [CI]: 261-315), and the PFS was 117 days (95% CI: 105-129). The median OS was higher among older patients (≥65 vs. <65 years: 325 days [95% CI: 264-385] vs. 285 days [95% CI: 252-317]; p = 0.028). The median OS was also higher in patients who received eribulin after fewer prior lines of chemotherapy (≤2 vs. >2 prior: 328 days [95% CI: 264-385] vs. 264 days [95% CI: 229-298]; p = 0.042).Discussion/Conclusion: These retrospective data suggest that eribulin can be successfully used in older patients with MBC. Eribulin treatment was more effective in earlier-line settings, which, while predictable, supports consideration of eribulin as a second-line treatment option.

KW - eribulin

KW - observation study

KW - real-world

KW - metastatic breast cancer

KW - older adults

KW - second-line

KW - Observation study

KW - Second-line treatment

KW - Eribulin

KW - Real-world data

KW - Metastatic breast cancer

KW - Older adults

UR - http://www.scopus.com/inward/record.url?scp=85144415888&partnerID=8YFLogxK

U2 - 10.1159/000526140

DO - 10.1159/000526140

M3 - Article

C2 - 36044833

SN - 0030-2414

VL - 100

SP - 666

EP - 673

JO - Oncology

JF - Oncology

IS - 12

ER -

Eribulin treatment for patients with metastatic breast cancer: The UK Experience - A Multicenter Retrospective Study

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this